Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technology drugs. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.
Frequently asked questions
What sector does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349) operate in?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349) current stock price?
As of the latest data, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd stock price is HK$2.61, with a previous close of HK$2.63. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd lost -HK$0.02 in the last trading session, representing a -0.57% loss.
What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349) current market capitalization?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd market cap is approximately 887.40 million.
What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349) Earnings Per Share (EPS)?
The trailing EPS is -HK$0.19.
What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349) EBITDA?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 45.50 million.
Does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349) pay dividends?
No. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd does not pay a dividend.
What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349) beta (volatility) score?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd has a beta of 0.086, indicating lower volatility than the overall market.
